NOVO NORDISK A/S |
Precio de cierre
Otros sitios de cotización
|
||
| - EUR | - |
|
| 14/06 | El consejero delegado de Novo Nordisk testificará en una audiencia del Senado de EE.UU. sobre el elevado coste de Ozempic y Wegovy | RE |
| 14/06 | UCB entierra a Novo; ¿está sobrevalorada Stellantis? |  |
Resumen de negocios
- productos para el tratamiento de la diabetes y la obesidad (92,6%);
- productos para el tratamiento de enfermedades raras (7,4%): destinados al tratamiento de la hemofilia, trastornos sanguíneos, trastornos hormonales, etc.
Las ventas netas se distribuyen geográficamente de la siguiente manera: Europa/Oriente Medio/África (21,9%), Estados Unidos (54,9%), Norteamérica (3,9%), China (7,2%) y otros (12,1%).
Ventas por actividad
| DKK en millones | 2022 | Peso | 2023 | Peso | Delta |
|---|---|---|---|---|---|
Diabetes and Obesity Care
92,6
%
| 156 412 | 88,4 % | 215 098 | 92,6 % | +37,52 % |
Rare Disease
7,4
%
| 20 542 | 11,6 % | 17 163 | 7,4 % | -16,45 % |
Ventas por región
| DKK en millones | 2022 | Peso | 2023 | Peso | Delta |
|---|---|---|---|---|---|
United States
54,9
%
| 84 656 | 47,8 % | 127 534 | 54,9 % | +50,65 % |
EMEA
21,9
%
| 44 236 | 25,0 % | 50 867 | 21,9 % | +14,99 % |
Rest of the World
12,1
%
| 25 402 | 14,4 % | 28 078 | 12,1 % | +10,53 % |
China
7,2
%
| 16 209 | 9,2 % | 16 687 | 7,2 % | +2,95 % |
Canada
3,9
%
| 6 451 | 3,6 % | 9 095 | 3,9 % | +40,99 % |
Directores
| Directores | Puesto | Edad | Desde |
|---|---|---|---|
| Chief Executive Officer | 58 | 01/01/91 | |
| Director of Finance/CFO | 53 | 01/01/99 | |
Stephen Gough
CTO | Chief Tech/Sci/R&D Officer | - | 01/10/15 |
Marcus Schindler
CTO | Chief Tech/Sci/R&D Officer | 57 | 01/01/18 |
| Chief Operating Officer | 54 | 01/01/92 | |
| Chief Tech/Sci/R&D Officer | 54 | 01/01/99 | |
Daniel Bohsen
IRC | Investor Relations Contact | - | 01/03/20 |
Tania Sabroe
HRO | Human Resources Officer | 47 | 01/01/07 |
| General Counsel | - | - | |
Sergey Manelis
PRN | Corporate Officer/Principal | - | 13/07/20 |
Administradores
| Administradores | Puesto | Edad | Desde |
|---|---|---|---|
Sylvie Grégoire
BRD | Director/Board Member | 62 | 19/03/15 |
Helge Lund
CHM | Chairman | 61 | 23/03/17 |
Martin MacKay
BRD | Director/Board Member | 68 | 01/03/18 |
Laurence Debroux
BRD | Director/Board Member | 54 | 21/03/19 |
Kasim Kutay
BRD | Director/Board Member | 59 | 23/03/17 |
Andreas Fibig
BRD | Director/Board Member | 62 | 01/03/18 |
Henrik Poulsen
BRD | Director/Board Member | 57 | 25/03/21 |
| Director/Board Member | 49 | 22/03/18 | |
Thomas Rantzau
BRD | Director/Board Member | 52 | 22/03/18 |
| Director/Board Member | 59 | 24/03/22 |
Clase de acciones
| Vote | Quantity | Flotante | Autocontrol | Total Float | |
|---|---|---|---|---|---|
| Acción A | 10 | 1 075 000 000 | 0 | 0 | 70,17 % |
| Acción B | 1 | 3 390 128 000 | 3 133 044 416 ( 92,42 %) | 51 700 000 ( 1,525 %) |
Participaciones
| Nombre | Acciones | % | Valoración |
|---|---|---|---|
NOVO NORDISK A/S 1.45% | 49 118 207 | 1.45% | 6 629 209 828 $ |
NNIT A/S 17.50% | 4 375 000 | 17.50% | 68 770 275 $ |
INNATE PHARMA 12.14% | 9 817 546 | 12.14% | 26 964 577 $ |
Información de la empresa
Empresas del grupo
| Nombre | Categoría y sector |
|---|---|
Novo Nordisk India Pvt Ltd.
 Novo Nordisk India Pvt Ltd. Medical/Nursing ServicesHealth Services Part of Novo Nordisk A/S, Novo Nordisk India Pvt Ltd. is a leading healthcare company founded in 1923 and headquartered in Denmark. The company is based in Bengaluru, India. Novo Nordisk's purpose is to drive change to defeat diabetes and other serious chronic diseases. |
Medical/Nursing Services
|
Velfærdsfonden for Novo Nordisk A/S
|
Investment Trusts/Mutual Funds
|
NNE A/S
 NNE A/S Engineering & ConstructionIndustrial Services Part of Novo Nordisk A/S, NNE A/S is a Danish company that supplies systems, consultancy and engineering services. The company is based in Soborg, Denmark. |
Engineering & Construction
|
World Diabetes Foundation
|
Investment Trusts/Mutual Funds
|
Novo Nordisk Health Care AG
 Novo Nordisk Health Care AG Pharmaceuticals: MajorHealth Technology Novo Nordisk Health Care AG engages in the production and distribution of chemical and pharmaceutical products as well as articles for diagnostic and therapeutic applications. It also specializes in the research in and development of products, therapeutic methods, and display techniques primarily used in the chemical, pharmaceutical, and diagnostic fields. The company was founded on August 10, 2000 and is headquartered in Zurich, Switzerland. |
Pharmaceuticals: Major
|
Novo Nordisk Finance (Netherlands) BV
|
Finance/Rental/Leasing
|
Novo Nordisk Region Europe A/S
 Novo Nordisk Region Europe A/S Financial ConglomeratesFinance Novo Nordisk Region Europe A/S holds ownership interests in other companies to undertake investment and financing activities. It offers service on an operational basis, including the placement of capital in companies and real estate. The company was founded September 14, 2001 and is headquartered in Bagsvaerd, Denmark. |
Financial Conglomerates
|
Ventas por actividad
Ventas por región
| Varia. 1 de ene. | Capi. | |
|---|---|---|
| +50,70 % | 791 mil M | |
| -7,15 % | 350 mil M | |
| +18,77 % | 328 mil M | |
| +8,79 % | 298 mil M | |
| +18,02 % | 246 mil M | |
| +1,27 % | 225 mil M | |
| +11,95 % | 218 mil M | |
| +3,68 % | 160 mil M | |
| -4,38 % | 156 mil M |
- Bolsa de valores
- Acciones
- Acción NOVO B
- Acción
- Empresa Novo Nordisk A/S
